Do analysts prefer BTMD or VYNE?

biote presently has a consensus price target of $2.75, suggesting a potential upside of 10.44%. Given biote's stronger consensus rating and higher probable upside, equities research analysts clearly believe biote is more favorable than VYNE Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score biote 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 VYNE Therapeutics 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75

Which has stronger earnings & valuation, BTMD or VYNE?

biote has higher revenue and earnings than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio biote $192.22M 0.49 $27.05M $0.44 5.66 VYNE Therapeutics $570K 47.26 -$26.48M -$0.38 N/A

Is BTMD or VYNE more profitable?

biote has a net margin of 8.29% compared to VYNE Therapeutics' net margin of -4,726.21%. biote's return on equity of -25.72% beat VYNE Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets biote 8.29% -25.72% 15.12% VYNE Therapeutics -4,726.21% -70.42% -63.46%

Do analysts recommend VYNE or FRMM?

Forum Markets has a consensus target price of $10.00, indicating a potential upside of 65.02%. Given Forum Markets' stronger consensus rating and higher probable upside, analysts clearly believe Forum Markets is more favorable than VYNE Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VYNE Therapeutics 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75 Forum Markets 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Do analysts prefer VYNE or JATT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VYNE Therapeutics 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75 JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings and valuation, VYNE or JATT?

JATT Acquisition has lower revenue, but higher earnings than VYNE Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio VYNE Therapeutics $570K 47.26 -$26.48M -$0.38 N/A JATT Acquisition N/A N/A $6.85M N/A N/A

Do analysts rate VYNE or THAR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VYNE Therapeutics 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75 Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate VYNE or TELO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VYNE Therapeutics 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75 Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

VYNE Therapeutics (VYNE) Competitors

$0.81 +0.05 (+6.15%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$0.71 -0.09 (-11.61%)

As of 07:22 AM Eastern

Compare

VYNE vs. BTMD, FRMM, JATT, THAR, and TELO

Should you buy VYNE Therapeutics stock or one of its competitors? MarketBeat compares VYNE Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with VYNE Therapeutics include biote (BTMD), Forum Markets (FRMM), JATT Acquisition (JATT), Tharimmune (THAR), and Telomir Pharmaceuticals (TELO). These companies are all part of the "pharmaceutical products" industry.

How does VYNE Therapeutics compare to biote?

biote (NASDAQ:BTMD) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

biote has higher revenue and earnings than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
biote	$192.22M	0.49	$27.05M	$0.44	5.66
VYNE Therapeutics	$570K	47.26	-$26.48M	-$0.38	N/A

In the previous week, biote had 1 more articles in the media than VYNE Therapeutics. MarketBeat recorded 1 mentions for biote and 0 mentions for VYNE Therapeutics. biote's average media sentiment score of 1.88 beat VYNE Therapeutics' score of 0.00 indicating that biote is being referred to more favorably in the media.

Company	Overall Sentiment
biote	Very Positive
VYNE Therapeutics	Neutral

biote has a net margin of 8.29% compared to VYNE Therapeutics' net margin of -4,726.21%. biote's return on equity of -25.72% beat VYNE Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
biote	8.29%	-25.72%	15.12%
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%

biote has a beta of 1.66, meaning that its stock price is 66% more volatile than the broader market. Comparatively, VYNE Therapeutics has a beta of 2, meaning that its stock price is 100% more volatile than the broader market.

biote presently has a consensus price target of $2.75, suggesting a potential upside of 10.44%. Given biote's stronger consensus rating and higher probable upside, equities research analysts clearly believe biote is more favorable than VYNE Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
VYNE Therapeutics	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

21.7% of biote shares are held by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are held by institutional investors. 32.4% of biote shares are held by insiders. Comparatively, 3.0% of VYNE Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

biote beats VYNE Therapeutics on 14 of the 17 factors compared between the two stocks.

How does VYNE Therapeutics compare to Forum Markets?

VYNE Therapeutics (NASDAQ:VYNE) and Forum Markets (NASDAQ:FRMM) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

83.8% of VYNE Therapeutics shares are held by institutional investors. Comparatively, 4.1% of Forum Markets shares are held by institutional investors. 3.0% of VYNE Therapeutics shares are held by insiders. Comparatively, 25.2% of Forum Markets shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Forum Markets has a consensus target price of $10.00, indicating a potential upside of 65.02%. Given Forum Markets' stronger consensus rating and higher probable upside, analysts clearly believe Forum Markets is more favorable than VYNE Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VYNE Therapeutics	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Forum Markets	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

VYNE Therapeutics has higher earnings, but lower revenue than Forum Markets. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VYNE Therapeutics	$570K	47.26	-$26.48M	-$0.38	N/A
Forum Markets	$9.41M	8.63	-$450.52M	-$36.07	N/A

In the previous week, Forum Markets had 9 more articles in the media than VYNE Therapeutics. MarketBeat recorded 9 mentions for Forum Markets and 0 mentions for VYNE Therapeutics. Forum Markets' average media sentiment score of 0.49 beat VYNE Therapeutics' score of 0.00 indicating that Forum Markets is being referred to more favorably in the news media.

Company	Overall Sentiment
VYNE Therapeutics	Neutral
Forum Markets	Neutral

Forum Markets has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat Forum Markets' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%
Forum Markets	N/A	-242.09%	-135.46%

VYNE Therapeutics has a beta of 2, meaning that its share price is 100% more volatile than the broader market. Comparatively, Forum Markets has a beta of 1.37, meaning that its share price is 37% more volatile than the broader market.

Summary

Forum Markets beats VYNE Therapeutics on 10 of the 17 factors compared between the two stocks.

How does VYNE Therapeutics compare to JATT Acquisition?

VYNE Therapeutics (NASDAQ:VYNE) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

JATT Acquisition has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. JATT Acquisition's return on equity of -49.58% beat VYNE Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%
JATT Acquisition	N/A	-49.58%	2.84%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VYNE Therapeutics	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, VYNE Therapeutics' average media sentiment score of 0.00 equaled JATT Acquisition'saverage media sentiment score.

Company	Overall Sentiment
VYNE Therapeutics	Neutral
JATT Acquisition	Neutral

83.8% of VYNE Therapeutics shares are owned by institutional investors. Comparatively, 48.0% of JATT Acquisition shares are owned by institutional investors. 3.0% of VYNE Therapeutics shares are owned by insiders. Comparatively, 20.0% of JATT Acquisition shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

JATT Acquisition has lower revenue, but higher earnings than VYNE Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VYNE Therapeutics	$570K	47.26	-$26.48M	-$0.38	N/A
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A

Summary

JATT Acquisition beats VYNE Therapeutics on 5 of the 8 factors compared between the two stocks.

How does VYNE Therapeutics compare to Tharimmune?

VYNE Therapeutics (NASDAQ:VYNE) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

In the previous week, VYNE Therapeutics' average media sentiment score of 0.00 equaled Tharimmune'saverage media sentiment score.

Company	Overall Sentiment
VYNE Therapeutics	Neutral
Tharimmune	Neutral

VYNE Therapeutics has a beta of 2, suggesting that its stock price is 100% more volatile than the broader market. Comparatively, Tharimmune has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market.

83.8% of VYNE Therapeutics shares are held by institutional investors. Comparatively, 1.2% of Tharimmune shares are held by institutional investors. 3.0% of VYNE Therapeutics shares are held by insiders. Comparatively, 6.7% of Tharimmune shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VYNE Therapeutics	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Tharimmune has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%
Tharimmune	N/A	-588.45%	-264.41%

Tharimmune has lower revenue, but higher earnings than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VYNE Therapeutics	$570K	47.26	-$26.48M	-$0.38	N/A
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A

Summary

VYNE Therapeutics beats Tharimmune on 7 of the 11 factors compared between the two stocks.

How does VYNE Therapeutics compare to Telomir Pharmaceuticals?

VYNE Therapeutics (NASDAQ:VYNE) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk and analyst recommendations.

VYNE Therapeutics has a beta of 2, meaning that its stock price is 100% more volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.25, meaning that its stock price is 125% less volatile than the broader market.

Telomir Pharmaceuticals has lower revenue, but higher earnings than VYNE Therapeutics. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VYNE Therapeutics	$570K	47.26	-$26.48M	-$0.38	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VYNE Therapeutics	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

83.8% of VYNE Therapeutics shares are held by institutional investors. 3.0% of VYNE Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Telomir Pharmaceuticals has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%

In the previous week, Telomir Pharmaceuticals had 2 more articles in the media than VYNE Therapeutics. MarketBeat recorded 2 mentions for Telomir Pharmaceuticals and 0 mentions for VYNE Therapeutics. VYNE Therapeutics' average media sentiment score of 0.00 equaled Telomir Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
VYNE Therapeutics	Neutral
Telomir Pharmaceuticals	Neutral

Summary

VYNE Therapeutics beats Telomir Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Get VYNE Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VYNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VYNE vs. The Competition

Export

Metric	VYNE Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$25.38M	$3.07B	$6.89B	$12.28B
Dividend Yield	N/A	2.05%	2.67%	9.39%
P/E Ratio	-2.13	20.20	27.07	23.95
Price / Sales	47.26	340.68	515.05	90.33
Price / Cash	N/A	27.11	26.68	47.25
Price / Book	0.97	4.20	10.62	6.14
Net Income	-$26.48M	$65.94M	$3.60B	$331.74M
7 Day Performance	13.61%	-3.05%	-1.26%	-1.82%
1 Month Performance	27.13%	-1.30%	1.07%	-1.45%
1 Year Performance	-33.24%	15.22%	23.63%	16.32%

VYNE Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VYNE VYNE Therapeutics	1.0692 of 5 stars	$0.81 +6.1%	N/A	-30.4%	$25.38M	$570K	N/A	30
BTMD biote	3.9927 of 5 stars	$2.19 -5.6%	$2.75 +25.6%	-38.1%	$87.19M	$192.22M	4.98	194	Positive News
FRMM Forum Markets	3.3 of 5 stars	$6.80 +4.9%	$10.00 +47.1%	N/A	$86.77M	$6.55M	N/A	7
JATT JATT Acquisition	N/A	$10.76 -6.4%	N/A	+506.8%	$86.35M	N/A	N/A	3	Gap Down
THAR Tharimmune	N/A	$2.27 -4.6%	N/A	+36.1%	$85.65M	N/A	N/A	2

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VYNE) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

VYNE Therapeutics (VYNE) Competitors

VYNE vs. BTMD, FRMM, JATT, THAR, and TELO

How does VYNE Therapeutics compare to biote?

Summary

How does VYNE Therapeutics compare to Forum Markets?

Summary

How does VYNE Therapeutics compare to JATT Acquisition?

Summary

How does VYNE Therapeutics compare to Tharimmune?

Summary

How does VYNE Therapeutics compare to Telomir Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VYNE vs. The Competition

VYNE Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

VYNE Therapeutics (VYNE) Competitors

VYNE vs. BTMD, FRMM, JATT, THAR, and TELO

How does VYNE Therapeutics compare to biote?

Which has stronger earnings & valuation, BTMD or VYNE?

Does the media prefer BTMD or VYNE?

Is BTMD or VYNE more profitable?

Which has more risk & volatility, BTMD or VYNE?

Do analysts prefer BTMD or VYNE?

Do insiders & institutionals hold more shares of BTMD or VYNE?

Summary

How does VYNE Therapeutics compare to Forum Markets?

Do institutionals & insiders have more ownership in VYNE or FRMM?

Do analysts recommend VYNE or FRMM?

Which has stronger valuation and earnings, VYNE or FRMM?

Does the media favor VYNE or FRMM?

Is VYNE or FRMM more profitable?

Which has more risk and volatility, VYNE or FRMM?

Summary

How does VYNE Therapeutics compare to JATT Acquisition?

Is VYNE or JATT more profitable?

Do analysts prefer VYNE or JATT?

Does the media favor VYNE or JATT?

Do institutionals & insiders have more ownership in VYNE or JATT?

Which has preferable earnings and valuation, VYNE or JATT?

Summary

How does VYNE Therapeutics compare to Tharimmune?

Does the media favor VYNE or THAR?

Which has more risk and volatility, VYNE or THAR?

Do insiders and institutionals have more ownership in VYNE or THAR?

Do analysts rate VYNE or THAR?

Is VYNE or THAR more profitable?

Which has better valuation & earnings, VYNE or THAR?

Summary

How does VYNE Therapeutics compare to Telomir Pharmaceuticals?

Which has more risk & volatility, VYNE or TELO?

Which has stronger valuation & earnings, VYNE or TELO?

Do analysts rate VYNE or TELO?

Do institutionals and insiders hold more shares of VYNE or TELO?

Is VYNE or TELO more profitable?

Does the media favor VYNE or TELO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VYNE vs. The Competition

VYNE Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools